New drug duo aims to shrink lung tumors in First-Line trial
NCT ID NCT07353957
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Petosemtamab and pembrolizumab
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced non-small cell lung cancer, potentially improving tumor shrinkage rates.
What could go wrong
This is an early-phase trial with only 180 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER - NON SMALL CELL SQUAMOUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Australia Site 1
RECRUITINGFrankston, Victoria, 3199, Australia
-
CHU Brest Hopital la Cavale Blanche
RECRUITINGBrest, 29609, France
-
Centre Hospitalier Intercommunal de Creteil (CHIC)
RECRUITINGCréteil, 94000, France
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, 28645, South Korea
-
Clinica Universidad de Navarra - Pamplona
RECRUITINGPamplona, 31008, Spain
-
Flinders Medical Centre
RECRUITINGBedford Park, South Australia, 5042, Australia
-
Florida Cancer Specialists - North
RECRUITINGSt. Petersburg, Florida, 33701-4553, United States
Contact Email: •••••@•••••
-
HC Hospitales SL
RECRUITINGMarbella, 29660, Spain
-
Hopital Nord Laennec
RECRUITINGNantes, 44093, France
-
Hospital Alvaro Cunqueiro
RECRUITINGVigo, 36312, Spain
-
Hospital Quironsalud Malaga
RECRUITINGMálaga, 29004, Spain
-
Hospital Universitario de Navarra
RECRUITINGPamplona, 31008, Spain
-
ICM - Montpellier Cancer Institute
RECRUITINGMontpellier, 34298, France
-
Kyungpook National University Chilgok Hospital
RECRUITINGDaegu, 41404, South Korea
-
Leiden University Medical Center
RECRUITINGLeiden, 2333, Netherlands
-
Memorial Sloan Kettering Cancer Center
RECRUITINGLong Island City, New York, 11101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START - Rioja
RECRUITINGLogroño, 26006, Spain
-
Severance Hospital - Yonsei University Health System
RECRUITINGSeoul, 3722, South Korea
-
Tennessee Site 1
RECRUITINGNashville, Tennessee, 37209, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Site 2
RECRUITINGChattanooga, Tennessee, 37403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Catholic University of Korea, St. Vincents Hospital
RECRUITINGSuwon, 16247, South Korea
-
Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi
RECRUITINGFlorence, 50134, Italy
-
Virginia Site 1
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Site 2
RECRUITINGBlacksburg, Virginia, 24060, United States